{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:50:51Z","timestamp":1791820251943,"version":"4.3.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"abstract":"\n Importance<\/jats:title>\n In trials targeting preclinical Alzheimer disease (AD), defined as amyloid pathology without cognitive symptoms, racial and ethnic differences in plasma phosphorylated tau 217 percentage (%p-tau217) may influence screening eligibility.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize racial and ethnic differences in %p-tau217 and determine whether associations between %p-tau217, cognition, and amyloid positron emission tomography (PET) differ across groups.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a cross-sectional analysis of AHEAD 3-45 screening participants conducted from July 2020 to October 2024 at 106 sites across 4 world regions. Adults aged 55 to 80 years with %p-tau217 measured before medical and cognitive exclusions (N\u2009=\u200915\u202f612) were included.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Self-reported race (Asian, Black, and White) and ethnicity (Hispanic and non-Hispanic) and apolipoprotein E \u03b54 (\n APOE<\/jats:italic>\n \u03b54) carrier status.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n %p-tau217 levels and associations of %p-tau217 with Preclinical Alzheimer Cognitive Composite 5 (PACC5) score and amyloid PET were evaluated across racial and ethnic groups using multivariable linear regression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 15\u202f612 participants, the mean (SD) age was 68.4 (6.2) years; 9941 (63.7%) were female and 5755 (36.9%) were\n APOE<\/jats:italic>\n \u03b54 carriers. %p-tau217 levels were lower among Asian, Black, and Hispanic participants than among White and non-Hispanic participants.\n APOE<\/jats:italic>\n \u03b54 status was associated with higher %p-tau217 across all groups. The association between\n APOE<\/jats:italic>\n \u03b54 status and %p-tau217 differed by race (\n APOE<\/jats:italic>\n \u03b54\u2009\u00d7\u2009race:\n F<\/jats:italic>\n 2,14\u202f973<\/jats:sub>\n \u2009=\u200910.06;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and ethnicity (\n APOE<\/jats:italic>\n \u03b54\u2009\u00d7\u2009ethnicity: \u03b2, 0.042; 95% CI, 0.017 to 0.067;\n P<\/jats:italic>\n \u2009=\u2009.005) (Asian: \u03b2, 0.05; 95% CI, 0.02 to 0.08;\n P<\/jats:italic>\n \u2009=\u2009.01; Black: \u03b2, 0.05; 95% CI, 0.03 to 0.08;\n P<\/jats:italic>\n \u2009=\u2009.002; Hispanic: \u03b2, 0.04; 95% CI, 0.02 to 0.07;\n P<\/jats:italic>\n \u2009=\u2009.005). The %p-tau217\u2013PACC5 association showed no pairwise differences across racial groups but differed by ethnicity (\u03b2, \u22120.53; 95% CI, \u22120.85 to \u22120.21;\n P<\/jats:italic>\n \u2009=\u2009.008) and\n APOE<\/jats:italic>\n \u03b54\u2009\u00d7\u2009ethnicity (\u03b2, 0.78; 95% CI, 0.26 to 1.30;\n P<\/jats:italic>\n \u2009=\u2009.02). The %p-tau217\u2013PET association showed no significant pairwise differences across racial groups but differed by ethnicity (\u03b2, \u22126.30; 95% CI, \u22129.10 to \u22123.51;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and\n APOE<\/jats:italic>\n \u03b54\u2009\u00d7\u2009ethnicity (\u03b2, 7.12; 95% CI, 2.52 to 11.73;\n P<\/jats:italic>\n \u2009=\u2009.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study, plasma %p-tau217 varied across racial and ethnic groups. Consistent %p-tau217\u2013PACC5 score and %p-tau217\u2013PET associations across racial groups support plasma-based screening before PET confirmation, while ethnicity-related findings warrant further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.3598","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:38Z","timestamp":1791819038000},"source":"Crossref","is-referenced-by-count":0,"title":["Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease"],"prefix":"10.1001","author":[{"given":"Doris P.","family":"Molina-Henry","sequence":"first","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Liu","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langford","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Dass","sequence":"additional","affiliation":[{"name":"Division of Aging and Dementia, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Clark","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine and Dentistry, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Day","sequence":"additional","affiliation":[{"name":"Mayo Clinic Jacksonville, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid R.","family":"Okhravi","sequence":"additional","affiliation":[{"name":"Goldrich Neurohealth Institute, Eastern Virginia Medical School at Old Dominion University, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Joshi","sequence":"additional","affiliation":[{"name":"Banner Health, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Cazares","sequence":"additional","affiliation":[{"name":"Sharp HealthCare, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Verghese","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venky","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"West","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[{"name":"Eisai, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[{"name":"Eisai, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Johnson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"},{"name":"Department of Physiology and Neuroscience, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[{"name":"Epstein Family Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"3","key":"noi260067r1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology.","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi260067r2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study.","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol"},{"issue":"10","key":"noi260067r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.35068","article-title":"Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors.","volume":"5","author":"Hajjar","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"noi260067r4","doi-asserted-by":"publisher","first-page":"e1491","DOI":"10.1212\/WNL.0000000000011599","article-title":"Amyloid PET imaging in self-identified non-Hispanic Black participants of the Anti-Amyloid in Asymptomatic Alzheimer\u2019s Disease (A4) Study.","volume":"96","author":"Deters","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"noi260067r5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.26819","article-title":"Eligibility rates among racially and ethnically diverse US participants in phase 2 and phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer disease.","volume":"95","author":"Grill","year":"2024","journal-title":"Ann Neurol"},{"issue":"3","key":"noi260067r6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of racial disparities in biomarkers for Alzheimer disease.","volume":"76","author":"Morris","year":"2019","journal-title":"JAMA Neurol"},{"issue":"7","key":"noi260067r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14364","article-title":"Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial.","volume":"4","author":"Raman","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"noi260067r8","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1038\/s41467-024-49859-w","article-title":"Baseline levels and longitudinal changes in plasma A\u00df42\/40 among Black and white individuals.","volume":"15","author":"Xiong","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"noi260067r9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2025.3217","article-title":"Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease.","volume":"82","author":"Salvad\u00f3","year":"2025","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi260067r10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70164","article-title":"Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.","volume":"17","author":"Molina-Henry","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"noi260067r11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71681","article-title":"More efficient screening for preclinical Alzheimer\u2019s clinical trials using mixture of experts.","volume":"22","author":"Langford","year":"2026","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi260067r12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: screening and baseline data from TRAILBLAZER-ALZ 3.","volume":"21","author":"Yaari","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"7","key":"noi260067r13","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1002\/alz.13027","article-title":"The structural and social determinants of Alzheimer\u2019s disease related dementias.","volume":"19","author":"Adkins-Jackson","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi260067r14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","article-title":"Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies.","volume":"11","author":"Sperling","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"noi260067r15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 Study: design of a prevention trial for Alzheimer\u2019s disease.","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"},{"key":"noi260067r16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.14283\/jpad.2024.112","article-title":"The AHEAD 3-45 Study: design and results of a novel screening process for a preclinical AD trial.","volume":"11","author":"Raman","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"noi260067r17","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.14283\/jpad.2024.88","article-title":"Estimating socio-economic status for Alzheimer\u2019s disease trials.","volume":"11","author":"Rentz","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"16","key":"noi260067r18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/diagnostics14161739","article-title":"PrecivityAD2 blood test: analytical validation of an LC-MS\/MS assay for quantifying plasma phospho-tau217 and non-phospho-tau217 peptide concentrations that are used with plasma amyloid-\u00df42\/40 in a multianalyte assay with algorithmic analysis for detecting brain amyloid pathology.","volume":"14","author":"Eastwood","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"noi260067r19","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u00df42\/40 ratio to identify presence of brain amyloid.","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi260067r20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2517-6161.1964.tb00553.x","article-title":"An analysis of transformations.","volume":"26","author":"Box","year":"1964","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"2","key":"noi260067r22","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure.","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat Theory Appl"},{"issue":"4","key":"noi260067r23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.14283\/jpad.2024.124","article-title":"Relationship between plasma p-tau217 and amyloid PET in racial and ethnic underrepresented groups (RE-URG) compared with non RE-URG in LEARN and A4.","volume":"11","author":"Molina-Henry","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"noi260067r24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","article-title":"Mixed pathology is more likely in black than white decedents with Alzheimer dementia.","volume":"85","author":"Barnes","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"noi260067r25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jalz.2016.06.2360","article-title":"Systematic review of dementia prevalence and incidence in United States race\/ethnic populations.","volume":"13","author":"Mehta","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi260067r26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3233\/JAD-210549","article-title":"Race-related association between APOE genotype and Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"83","author":"Qin","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"noi260067r27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","article-title":"APOE genotype and Alzheimer disease risk across age, sex, and population ancestry.","volume":"80","author":"Belloy","year":"2023","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi260067r28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","article-title":"Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project.","volume":"79","author":"Manly","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi260067r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25134","article-title":"Trends in poor health indicators among Black and Hispanic middle-aged and older adults in the United States, 1999-2018.","volume":"3","author":"Odlum","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"24","key":"noi260067r30","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1001\/jama.2019.19428","article-title":"Addressing challenges and implications of national surveillance for racial\/ethnic disparities in diabetes.","volume":"322","author":"Matsushita","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"noi260067r31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71406","article-title":"Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.","volume":"22","author":"Bolton","year":"2026","journal-title":"Alzheimers Dement"},{"issue":"6","key":"noi260067r32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"7","key":"noi260067r33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community.","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"noi260067r34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-023-01563-4","article-title":"Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease.","volume":"11","author":"Ali","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"noi260067r35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10072-023-07076-1","article-title":"Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer\u2019s disease: racial differences.","volume":"45","author":"Xu","year":"2024","journal-title":"Neurol Sci"},{"issue":"3","key":"noi260067r36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaneurol.2025.5329","article-title":"Uniform amyloid thresholds across populations.","volume":"83","author":"Vanderlip","year":"2026","journal-title":"JAMA Neurol"},{"key":"noi260067r37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.088364","article-title":"Effect of kidney function on plasma pTau217 concentrations using different pTau217 assays.","volume":"20","author":"Algeciras-Schimnich","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi260067r38","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance.","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi260067r39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/13872877241299047","article-title":"Ethnic and racial influences on blood biomarkers for Alzheimer\u2019s disease: a systematic review.","volume":"103","author":"Kjaergaard","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"14","key":"noi260067r40","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","article-title":"Association of plasma biomarkers of alzheimer disease with cognition and medical comorbidities in a biracial cohort.","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"noi260067r41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jamaneurol.2025.5670","article-title":"Sex differences in p-tau217, tau aggregation, and cognitive decline.","volume":"83","author":"Coughlan","year":"2026","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi260067r42","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ana.26460","article-title":"Tau mediates synergistic influence of vascular risk and A\u00df on cognitive decline.","volume":"92","author":"Yau","year":"2022","journal-title":"Ann Neurol"},{"key":"noi260067r21","doi-asserted-by":"crossref","DOI":"10.32614\/R.manuals","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2026"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2854981\/jamaneurology_molinahenry_2026_oi_260067_1790869909.634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:39Z","timestamp":1791819039000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2854981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.3598","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}